JPRN-UMIN000001094已完成2 期
Phase II study of caffeine combined chemotherapy in patients with high- grade bone and soft tissue tumor - Caffeine combined chemotherapy for high- grade bone and soft tissue tumor pII
Group for "Caffeine combined chemotherapy in patients with high-grade bone and soft tissue tumor"0 个研究点目标入组 100 人开始时间: 2008年3月25日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 5years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1.sever drug allergy 2.uncontrolled diabetes mellitus 3.uncontrolled hypertension 4.women during pregnancy
研究者
相似试验
已完成
2 期
A Phase II study of combination chemotherapy including Bortezomib in pediatric patients with relapsed acute lymphoblastic leukemia (Investigator-initiated clinical trial)A high-risk group of pediatric patients with first relapse of ALLor refractory ALL (patients who develop 2nd or subsequent relapse, relapse after hematopoietic cell transplantation or fail to achieve remission induction with one or more therapies).JPRN-UMIN000023815Department of Pediatric Oncology, National Cancer Center Hospital22
进行中（未招募）
2 期
Phase II study of 4-drug combination chemotherapy in patients with non-small cell lung cancer harboring EGFR active mutation.on-small cell lung cancerJPRN-jRCTs031180157Kurata Takayasu35
已完成
2 期
Phase II study of combination chemotherapy of Carboplatin, Pemetrexed, Bevacizumab and Erlotinib in patients with advanced non-squamous non-small cell lung cancer harboring EGFR active mutation.JPRN-UMIN000029476orth East Japan Study Group (NEJSG)16
尚未招募
1 期
Phase 1/2 study of combination chemotherapy with Carboplatin, nab-Paclitaxel, and Bevacizumab for advanced non-squamous non-small cell lung canceron-squamous Non-small-cell Lung CancerJPRN-UMIN000016735Hiroshima Asa City Hospital35
尚未招募
不适用
Phase 2 study of combination chemotherapy(VBL/PSL, MTX, 6MP) in patients with primary untreated adult langerhans cell histiocytosisadult langerhans cell histiocytosisJPRN-UMIN000006016Department of Hematology, International Medical Center, Saitama Medical University5